TVAX Biomedical, LLC
TVAX Biomedical was formed to commercialize a novel immunologic approach to cancer treatment. TVAX's personalized cancer treatment, TVAX Immunotherapy, used the natural resources of the cancer patient's own immune system to generate cancer specific killer T cells. Killer T cells that are delivered into the bloodstream of individuals with cancer will enter cancer tissue, ill cancer cells and reject growing cancers.
TVAX Immunotherapy was demonstrated to be safe and effective in pre-clinical and phase I/II human studies in a wide array of cancer types. TVAX Biomedical currently has an active IND from the FDA and is preparing to perform a pivotal phase III trial to test TVAX Immunotherapy as a treatment for brain cancer. TVAX has U.S. and European patents on the technology. Founded: 1999. Location: Lenexa, KS
Flint Hills Scientific,LLC
Multidisciplinary research team with expertise in a number of scientific areas. Flint Hills Scientific, LLC, has become a worldwide leader in real-time biomedical signal analysis and automated seizure detection and prediction. The company has received a number of federal grants (Small Business Innovation Research (SBIR) Phase I and Phase II) and several Cooperative Research and Development Agreement (CRADA) grants. Founded: 1996. Location: Lawrence, Kansas. (KUMC)
Immunogenetix Therapeutics, Inc.
ImmunoGenetix Therapeutics, Inc. is an early stage biotechnology company developing advanced DNA-based therapies for the prevention and treatment of HIV infection. DNA-based therapies offer significant advantages over recombinant protein therapies, including an enhanced cellular immune response and long term protection against viral diseases that require cellular immunity (e.g. HIV). The Company has exclusive worldwide rights to proprietary therapeutic candidates and supporting technologies being developed at the Marion Merrell Dow Laboratory of Viral Pathogenesis at the University of Kansas Medical Center. The director of this laboratory, Dr. Opendra Narayan, is a world renowned researcher in HIV who has developed a novel DNA-based therapeutic strategy to prevent and treat HIV infection. Dr. Narayan is evaluating these proprietary therapeutic candidates using a monkey animal model developed in his laboratory that closely mimics the HIV infection that occurs in humans. Several therapeutic candidates have completed initial efficacy studies in monkeys with promising results. Founded: 2002 Location: Lenexa KS
XenoTech,LLC
XenoTech was formed to manufacture products and to provide services to guide the discovery and development of drugs and other consumable products, such as food addictives, fragrances, and cosmetics. XenoTech specializes in the development and application of in vitro techniques for examining the metabolism of drugs and other chemicals for pharma-ceutical firms, chemical companies, academic institutions, and regulatory agencies, such as the United States Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA). XenoTech ’s products and services are designed to provide pre-clinical safety information of the type recommended by the FDA to predict inter-individual variability in drug safety and efficacy, and to predict or explain adverse drug-drug interactions. Founded: 1995. Location: Kansas City, Kansas (KUMC)
NephroGenex, Inc.
NephroGenex, is a start up utilizing technology developed in part at the University of Kansas Medical Center, is focused on the treatment of end stage renal disease (ESRD). It accounts for up to 15% of the entire health care budget in the United States , with annual costs estimated at $24 billion. In spite of the enormous socioeconomic burden, renal diseases are dramatically underserved by the pharmaceutical industry in contrast to cancer, cardiovascular disease, neurological diseases and diabetes. The recently determined polygenic etiology of the leading renal diseases and the related difficulty in identifying and validating drug targets and appropriate patient populations, are major hurdles for kidney disease drug development.
NephroGenex is applying the latest advances in molecular profiling technologies to unravel the complex pathologies found in kidney disease and overcome long standing obstacles for drug development in this field. The Company is acquiring commercial rights to clinical-stage candidates that exhibit activity toward established renal pathology, and determining renal molecular profiles and biomarkers that identify patients that are more likely to respond to therapy. The resulting molecular-based patient stratification can dramatically reduce the cost, time and risk of later stage clinical trials, and improve the prospects for achieving significant treatment effects. The Company is also applying renal molecular profiling to identify and validate novel molecular targets for the leading kidney diseases. (Founded: 2006. Location: Cary, NC.)
This page last updated: May, 17, 2008
©
The University of Kansas Medical Center